Torrent Pharmaceuticals Limited, commonly known as Torrent Pharma, is a prominent player in the global pharmaceutical industry, headquartered in Ahmedabad, India. Founded in 1959, the company has established a strong presence in various operational regions, including North America, Europe, and emerging markets across Asia and Africa. Specialising in the development, manufacturing, and marketing of a diverse range of generic and branded pharmaceuticals, Torrent Pharma focuses on therapeutic areas such as cardiovascular, central nervous system, and anti-infectives. The company is recognised for its commitment to quality and innovation, which has led to significant milestones, including a robust portfolio of over 200 products. With a strong market position, Torrent Pharmaceuticals has garnered accolades for its research and development capabilities, making it a trusted name in the industry. Its dedication to improving patient outcomes through affordable healthcare solutions sets it apart in a competitive landscape.
How does Torrent Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Torrent Pharmaceuticals's score of 29 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Torrent Pharmaceuticals reported total emissions of approximately 87,529,000 kg CO2e, comprising 8,937,000 kg CO2e from Scope 1 and 78,592,000 kg CO2e from Scope 2. The previous year, 2023, emissions were about 91,562,000 kg CO2e, with Scope 1 emissions at 15,294,000 kg CO2e and Scope 2 at 76,268,000 kg CO2e. In 2022, the company recorded total emissions of around 124,099,000 kg CO2e, with Scope 1 at 28,009,000 kg CO2e and Scope 2 at 98,916,000 kg CO2e. Despite these figures, Torrent Pharmaceuticals has not disclosed specific reduction targets or initiatives as part of their climate commitments. The emissions data is cascaded from Torrent Pharmaceuticals Limited, indicating a corporate family relationship. The company has not reported any Scope 3 emissions data, which typically includes indirect emissions from the supply chain and product use. Overall, while Torrent Pharmaceuticals has made strides in tracking and reporting emissions, further transparency regarding reduction strategies and commitments would enhance their climate action profile.
Access structured emissions data, company-specific emission factors, and source documents
2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|
Scope 1 | 28,072,000 | 00,000,000 | 00,000,000 | 0,000,000 |
Scope 2 | 96,026,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Torrent Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.